S&CO Inc’s Neurocrine Biosciences NBIX Stock Holding History

S&CO Inc’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$922K	Hold	7,000	–	–	0.06%	143
2025 Q4	$992K	Hold	7,000	–	–	0.06%	141
2025 Q3	$982K	Hold	7,000	–	–	0.06%	146
2025 Q2	$879K	Buy	7,000 +2,000	+40%	+$229K	0.06%	148
2025 Q1	$553K	Hold	5,000	–	–	0.04%	169
2024 Q4	$682K	Hold	5,000	–	–	0.05%	158
2024 Q3	$576K	Hold	5,000	–	–	0.04%	171
2024 Q2	$688K	Hold	5,000	–	–	0.05%	162
2024 Q1	$689K	Buy	+5,000	New	+$683K	0.05%	158

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

S&CO Inc's NBIX Position: Q1 2026 in Review

S&CO Inc held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 7,000 shares worth $922K. The position accounts for 0.06% of the portfolio, ranked #143.

S&CO Inc first reported a position in NBIX in Q1 2024 and has held it in 9 quarters since. The position peaked at $992K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

S&CO Inc held 7,000 shares of Neurocrine Biosciences worth $922K as of Q1 2026.
S&CO Inc left its Neurocrine Biosciences share count unchanged in Q1 2026.
Neurocrine Biosciences made up 0.06% of S&CO Inc's portfolio in Q1 2026, its #143 holding.
S&CO Inc first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 9 quarters since.
S&CO Inc's Neurocrine Biosciences position peaked at $992K in Q4 2025.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on S&CO Inc's 13F filing for Q1 2026, filed 7 May 2026.